tiprankstipranks
Trending News
More News >
Ascendis Pharma A/S (ASND)
:ASND
US Market
Advertisement

Ascendis Pharma (ASND) Stock Forecast & Price Target

Compare
613 Followers
See the Price Targets and Ratings of:

ASND Analyst Ratings

Strong Buy
14Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Ascendis
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ASND Stock 12 Month Forecast

Average Price Target

$231.86
▲(24.26% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Ascendis Pharma in the last 3 months. The average price target is $231.86 with a high forecast of $306.00 and a low forecast of $194.00. The average price target represents a 24.26% change from the last price of $186.59.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"124":"$124","307":"$307","169.75":"$169.8","215.5":"$215.5","261.25":"$261.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":306,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$306.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":231.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$231.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":194,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$194.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[124,169.75,215.5,261.25,307],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,174.48,184.59692307692308,194.71384615384613,204.83076923076922,214.9476923076923,225.06461538461537,235.18153846153845,245.29846153846154,255.4153846153846,265.53230769230765,275.64923076923077,285.7661538461538,295.88307692307694,{"y":306,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,174.48,178.89384615384614,183.3076923076923,187.72153846153844,192.13538461538462,196.54923076923077,200.96307692307693,205.37692307692308,209.79076923076923,214.2046153846154,218.61846153846153,223.0323076923077,227.44615384615386,{"y":231.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,174.48,175.98153846153846,177.4830769230769,178.98461538461538,180.48615384615383,181.9876923076923,183.48923076923077,184.99076923076922,186.4923076923077,187.99384615384616,189.4953846153846,190.99692307692308,192.49846153846153,{"y":194,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":136.53,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":156.58,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151.43,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":167.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":174.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$306.00Average Price Target$231.86Lowest Price Target$194.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ASND
TipRanks AITipRanks
Not Ranked
TipRanks
$161
Hold
-13.71%
Downside
Reiterated
07/31/25
Ascendis Pharma's stock score is primarily impacted by its weak financial performance and technical analysis, indicating financial instability and bearish market trends. While the earnings call provides some positive developments, the company faces significant profitability challenges and market uncertainties.
Morgan Stanley Analyst forecast on ASND
Maxwell SkorMorgan Stanley
Morgan Stanley
$250
Buy
33.98%
Upside
Reiterated
08/04/25
Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)Overweight rating with unchanged Price Target but EPS estimates revised (F25: -5.23 to -5.16; F26: 0.60 to 0.59).
Cantor Fitzgerald Analyst forecast on ASND
Li WatsekCantor Fitzgerald
Cantor Fitzgerald
$200
Buy
7.19%
Upside
Reiterated
08/04/25
Ascendis Pharma (ASND) Receives a Buy from Cantor FitzgeraldCantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and $200.00 price target on Ascendis Pharma (NASDAQ: ASND).
TD Cowen Analyst forecast on ASND
Yaron WerberTD Cowen
TD Cowen
$194
Buy
3.97%
Upside
Reiterated
07/31/25
TD Cowen Keeps Their Buy Rating on Ascendis Pharma (ASND)
J.P. Morgan Analyst forecast on ASND
Jessica FyeJ.P. Morgan
J.P. Morgan
$245$254
Buy
36.13%
Upside
Reiterated
07/29/25
J.P. Morgan Sticks to Their Buy Rating for Ascendis Pharma (ASND)JPMorgan analyst Jessica Fye raised the price target on Ascendis Pharma (NASDAQ: ASND) to $254.00 (from $245.00) while maintaining a Overweight rating.
Jefferies Analyst forecast on ASND
Kelly ShiJefferies
Jefferies
$233$235
Buy
25.94%
Upside
Reiterated
07/29/25
Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Incyte (INCY)…we raise Skytrofa peak sales from €698M (adj) to €716M and PT from $233 to $235.
Leerink Partners Analyst forecast on ASND
Joseph SchwartzLeerink Partners
Leerink Partners
$200
Buy
7.19%
Upside
Reiterated
07/28/25
Ascendis Pharma's Strong Market Performance and Potential Drive Buy Recommendation
Bank of America Securities Analyst forecast on ASND
Tazeen AhmadBank of America Securities
Bank of America Securities
$216$217
Buy
16.30%
Upside
Reiterated
07/28/25
Bullish Outlook on Ascendis Pharma: FDA Approval and Anticipated Product Launches Drive Buy Rating
Wedbush Analyst forecast on ASND
Yun ZhongWedbush
Wedbush
$212
Buy
13.62%
Upside
Assigned
07/28/25
Buy Rating for Ascendis Pharma Driven by Skytrofa's FDA Approval and Market Potential
Citi
$213$243
Buy
30.23%
Upside
Reiterated
07/14/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Biogen (NASDAQ: BIIB)
UBS
$197$306
Buy
64.00%
Upside
Reiterated
07/09/25
Ascendis Pharma (ASND) Gets a Buy from UBS
Wells Fargo Analyst forecast on ASND
Derek ArchilaWells Fargo
Wells Fargo
$100$289
Buy
54.89%
Upside
Reiterated
07/08/25
Positive Outlook for Ascendis Pharma Driven by Yorvipath's Growing Adoption and Revenue Potential
RBC Capital Analyst forecast on ASND
Luca IssiRBC Capital
RBC Capital
$210
Buy
12.55%
Upside
Reiterated
07/07/25
RBC Capital Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
Oppenheimer Analyst forecast on ASND
Leland GershellOppenheimer
Oppenheimer
$215$224
Buy
20.05%
Upside
Reiterated
06/13/25
Ascendis Pharma price target raised to $224 from $215 at OppenheimerAscendis Pharma price target raised to $224 from $215 at Oppenheimer
Stifel Nicolaus Analyst forecast on ASND
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$212
Buy
13.62%
Upside
Reiterated
05/27/25
Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ASND
TipRanks AITipRanks
Not Ranked
TipRanks
$161
Hold
-13.71%
Downside
Reiterated
07/31/25
Ascendis Pharma's stock score is primarily impacted by its weak financial performance and technical analysis, indicating financial instability and bearish market trends. While the earnings call provides some positive developments, the company faces significant profitability challenges and market uncertainties.
Morgan Stanley Analyst forecast on ASND
Maxwell SkorMorgan Stanley
Morgan Stanley
$250
Buy
33.98%
Upside
Reiterated
08/04/25
Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)Overweight rating with unchanged Price Target but EPS estimates revised (F25: -5.23 to -5.16; F26: 0.60 to 0.59).
Cantor Fitzgerald Analyst forecast on ASND
Li WatsekCantor Fitzgerald
Cantor Fitzgerald
$200
Buy
7.19%
Upside
Reiterated
08/04/25
Ascendis Pharma (ASND) Receives a Buy from Cantor FitzgeraldCantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and $200.00 price target on Ascendis Pharma (NASDAQ: ASND).
TD Cowen Analyst forecast on ASND
Yaron WerberTD Cowen
TD Cowen
$194
Buy
3.97%
Upside
Reiterated
07/31/25
TD Cowen Keeps Their Buy Rating on Ascendis Pharma (ASND)
J.P. Morgan Analyst forecast on ASND
Jessica FyeJ.P. Morgan
J.P. Morgan
$245$254
Buy
36.13%
Upside
Reiterated
07/29/25
J.P. Morgan Sticks to Their Buy Rating for Ascendis Pharma (ASND)JPMorgan analyst Jessica Fye raised the price target on Ascendis Pharma (NASDAQ: ASND) to $254.00 (from $245.00) while maintaining a Overweight rating.
Jefferies Analyst forecast on ASND
Kelly ShiJefferies
Jefferies
$233$235
Buy
25.94%
Upside
Reiterated
07/29/25
Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Incyte (INCY)…we raise Skytrofa peak sales from €698M (adj) to €716M and PT from $233 to $235.
Leerink Partners Analyst forecast on ASND
Joseph SchwartzLeerink Partners
Leerink Partners
$200
Buy
7.19%
Upside
Reiterated
07/28/25
Ascendis Pharma's Strong Market Performance and Potential Drive Buy Recommendation
Bank of America Securities Analyst forecast on ASND
Tazeen AhmadBank of America Securities
Bank of America Securities
$216$217
Buy
16.30%
Upside
Reiterated
07/28/25
Bullish Outlook on Ascendis Pharma: FDA Approval and Anticipated Product Launches Drive Buy Rating
Wedbush Analyst forecast on ASND
Yun ZhongWedbush
Wedbush
$212
Buy
13.62%
Upside
Assigned
07/28/25
Buy Rating for Ascendis Pharma Driven by Skytrofa's FDA Approval and Market Potential
Citi
$213$243
Buy
30.23%
Upside
Reiterated
07/14/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (NASDAQ: ASND) and Biogen (NASDAQ: BIIB)
UBS
$197$306
Buy
64.00%
Upside
Reiterated
07/09/25
Ascendis Pharma (ASND) Gets a Buy from UBS
Wells Fargo Analyst forecast on ASND
Derek ArchilaWells Fargo
Wells Fargo
$100$289
Buy
54.89%
Upside
Reiterated
07/08/25
Positive Outlook for Ascendis Pharma Driven by Yorvipath's Growing Adoption and Revenue Potential
RBC Capital Analyst forecast on ASND
Luca IssiRBC Capital
RBC Capital
$210
Buy
12.55%
Upside
Reiterated
07/07/25
RBC Capital Reaffirms Their Buy Rating on Ascendis Pharma (ASND)
Oppenheimer Analyst forecast on ASND
Leland GershellOppenheimer
Oppenheimer
$215$224
Buy
20.05%
Upside
Reiterated
06/13/25
Ascendis Pharma price target raised to $224 from $215 at OppenheimerAscendis Pharma price target raised to $224 from $215 at Oppenheimer
Stifel Nicolaus Analyst forecast on ASND
Alex Thompson CFAStifel Nicolaus
Stifel Nicolaus
$212
Buy
13.62%
Upside
Reiterated
05/27/25
Ascendis Pharma (ASND) Gets a Buy from Stifel Nicolaus
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ascendis Pharma

1 Month
xxx
Success Rate
11/15 ratings generated profit
73%
Average Return
+6.66%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 73.33% of your transactions generating a profit, with an average return of +6.66% per trade.
3 Months
xxx
Success Rate
20/26 ratings generated profit
77%
Average Return
+11.05%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 76.92% of your transactions generating a profit, with an average return of +11.05% per trade.
1 Year
Tazeen AhmadBank of America Securities
Success Rate
25/29 ratings generated profit
86%
Average Return
+24.49%
reiterated a buy rating 11 days ago
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 86.21% of your transactions generating a profit, with an average return of +24.49% per trade.
2 Years
xxx
Success Rate
15/15 ratings generated profit
100%
Average Return
+56.05%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +56.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASND Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
9
7
7
9
5
Buy
22
23
30
40
31
Hold
13
8
3
2
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
44
38
40
51
38
In the current month, ASND has received 36 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the past 3 months is 231.86.
Each month's total comprises the sum of three months' worth of ratings.

ASND Financial Forecast

ASND Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.

ASND Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

ASND Stock Forecast FAQ

What is ASND’s average 12-month price target, according to analysts?
Based on analyst ratings, Ascendis Pharma A/S’s 12-month average price target is 231.86.
    What is ASND’s upside potential, based on the analysts’ average price target?
    Ascendis Pharma A/S has 24.26% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ASND a Buy, Sell or Hold?
          Ascendis Pharma A/S has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ascendis Pharma A/S’s price target?
            The average price target for Ascendis Pharma A/S is 231.86. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $306.00 ,the lowest forecast is $194.00. The average price target represents 24.26% Increase from the current price of $186.59.
              What do analysts say about Ascendis Pharma A/S?
              Ascendis Pharma A/S’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of ASND?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis